Skip to main
  1. Stocks
  2. Odyssey Therapeutics Inc
  3. Forecast
ODTX

ODTX Stock Forecast & Price Target

ODTX Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Odyssey Therapeutics is supported by a first-in-class oral RIPK2 scaffolding inhibitor, OD-001, that targets an upstream innate-immune node to suppress multiple validated UC cytokines at once, a mechanism orthogonal to approved therapies and potentially useful as both monotherapy and combination backbone. Its Phase 2a data are encouraging, with a 2.6-point modified Mayo reduction (p<0.001), 27% clinical remission at 20 mg BID, and no serious adverse events, serious infections, treatment-related discontinuations, or liver-function signals, while remission held up in advanced-therapy-experienced patients at 25%. Financially, the company ended 2Q26 with $433M in cash and equivalents, and the model assumes roughly $2.95B U.S. and $1.6B ex-U.S. peak sales for OD-001, plus upside from OD-002, OD-003, and the rest of the pipeline.

Bears say

Odyssey Therapeutics is viewed negatively because its lead asset OD-001 is only in Phase 2a/b, leaving substantial clinical-development risk that could easily delay or derail the program if primary endpoints are missed or efficacy proves lower than expected. The company also faces meaningful regulatory and commercial uncertainty, with FDA discussions still needed, a crowded autoimmune and inflammatory disease landscape, and the possibility that combination or novel-target approaches fail to outperform existing therapies. Financially, the risk profile is amplified by an estimated ~48M shares post-IPO, expected GAAP EPS of ($1.13) in 3Q26 and ($6.13) in 2026, and a projected GAAP net loss and operating cash flow burn until 2034, implying continued dependence on external financing and added volatility around the early November lock-up expiration.

ODTX has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Odyssey Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

ODTX Analyst Forecast & Price Prediction

Get the latest ODTX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ODTX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Odyssey Therapeutics Inc (ODTX) Forecast

Analysts have given ODTX a Buy based on their latest research and market trends.

According to 6 analysts, ODTX has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Odyssey Therapeutics Inc (ODTX)


ODTX Analyst Forecast & Price Prediction

Get the latest ODTX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ODTX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ODTX stock data and trends